Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV.

BACKGROUND: Systemic chemotherapy typically converts previously unresectable liver metastases (LM) from colorectal cancer to curative intent resection in ∼15% of patients. This European multicenter phase II trial tested whether hepatic artery infusion (HAI) with triplet chemotherapy and systemic cet...

ver descrição completa

Detalhes bibliográficos
Autor principal: Lévi, FA (author)
Outros Autores: Boige, V (author), Hebbar, M (author), Smith, D (author), Lepère, C (author), Focan, C (author), Karaboué, A (author), Guimbaud, R (author), Carvalho, C (author), Tumolo, S (author), Innominato, P (author), Ajavon, Y (author), Truant, S (author), Castaing, D (author), De Baere, T (author), Kunstlinger, F (author), Bouchahda, M (author), Afshar, M (author), Rougier, P (author), Adam, R (author), Ducreux, M (author), Association Internationale pour Recherche sur Temps Biologique et Chronothérapie (ARTBC International) (author)
Formato: article
Idioma:eng
Publicado em: 2017
Assuntos:
Cetuximab
Clinical trials
Colorectal neoplasms
Antineoplastic combined chemotherapy protocols
Liver neoplasms
Texto completo:http://hdl.handle.net/10400.10/1883
País:Portugal
Oai:oai:repositorio.hff.min-saude.pt:10400.10/1883

Texto Completo

http://hdl.handle.net/10400.10/1883

Registos relacionados